Sarepta Announces FDA’s Approval of Updated Elevidys Prescribing Information

Nov 18, 2025 - 03:00
 0  2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2025-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for Elevidys (delandistrogene...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0